



Advances in the Delivery of DNA and RNA Therapeutics to the Eye

Guest Editors:

Assist. Prof. Marika Ruponen

School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70210 Kuopio, Finland

Senior Researcher Astrid

Subrizi

School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70210 Kuopio, Finland

Deadline for manuscript submissions:

closed (31 December 2020)

Message from the Guest Editors

Dear Colleagues,

The eye is an appealing target organ for DNA- and RNA-based therapies. The eye is enclosed and relatively immune privileged due to an efficient blood–retina barrier and little lymphatic drainage. Viral-based vectors are currently the most promising option for gene replacement in the treatment of inherited retinal diseases. Viral vectors, however, require invasive subretinal injections, and concerns related to their safety, repeated dosing, and large-scale production have been only partially addressed. For this reason, non-viral alternatives should be considered and explored. Research in this field has expanded to find solutions for prolonged expression of therapeutic proteins or gene silencing in the treatment of more common non-genetic retinal diseases. Other research efforts include the development of delivery strategies that allow the retinal administration of DNA and RNA therapeutics via less invasive routes, such as intravitreal, periocular, or systemic delivery.

This Special Issue aims to highlight the current progress in ocular delivery of DNA and RNA therapeutics.

Assist. Prof. Marika Ruponen
Senior Researcher Astrid Subrizi
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma